Cargando…

Single center validation of routine blastocyst biopsy implementation

PURPOSE: The study aims to contrast the efficacy of trophectoderm biopsy preimplantation genetic screening (PGS)/vitrification (VTF)-all cycles to past treatment protocols. Specifically, do these applied technologies increase live birth rates on a per cycle/first transfer basis? MATERIALS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Whitney, John B., Schiewe, Mitchel C., Anderson, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125149/
https://www.ncbi.nlm.nih.gov/pubmed/27544278
http://dx.doi.org/10.1007/s10815-016-0792-3
_version_ 1782469939510116352
author Whitney, John B.
Schiewe, Mitchel C.
Anderson, Robert E.
author_facet Whitney, John B.
Schiewe, Mitchel C.
Anderson, Robert E.
author_sort Whitney, John B.
collection PubMed
description PURPOSE: The study aims to contrast the efficacy of trophectoderm biopsy preimplantation genetic screening (PGS)/vitrification (VTF)-all cycles to past treatment protocols. Specifically, do these applied technologies increase live birth rates on a per cycle/first transfer basis? MATERIALS AND METHODS: An observational, retrospective cohort study of first transfer outcomes was performed in two groups. Group 1 (PGS) included PGS/VTF-all cycles, and group 2 (no PGS) included the first transfer from non-PGS fresh cycles or VTF-ALL cycles. In group 1, all blastocysts were biopsied on days 5/6, vitrified and array CGH performed. Group 2 patients had embryo transfers on day 3 or day 5. All blastocysts were vitrified and warmed according to μS-VTF protocols. Clinical pregnancies and implantation were confirmed by ultrasound and live birth information attained. Results were stratified by age with donor cycles excluded, and to eliminate bias, the same groups were then validated on a per cycle basis. Chi-squared used to determine significance. RESULTS: Analyzing 287 embryo transfers and 1,000+ PGS-tested blastocysts, an overall 97 % increase in live births favored group 1 (PGS). When utilizing PGS/VTF-ALL cycles, patients under 43 years old exhibited higher implantation, clinical pregnancy, and ongoing/live birth rates. Re-analyzing the data to include all cycles initiated revealed higher live birth rates in group 1 age groups ≤34 and 38–40 years old. CONCLUSION: Validating PGS on a per cycle basis eliminated data bias by including patients without blastocysts to biopsy or euploid embryos. Clearly, PGS uses blastocysts more efficiently to achieve success, while many women over 40 may benefit most by understanding why some failures occur. SUPPORT: None ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10815-016-0792-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5125149
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-51251492016-12-12 Single center validation of routine blastocyst biopsy implementation Whitney, John B. Schiewe, Mitchel C. Anderson, Robert E. J Assist Reprod Genet Assisted Reproduction Technologies PURPOSE: The study aims to contrast the efficacy of trophectoderm biopsy preimplantation genetic screening (PGS)/vitrification (VTF)-all cycles to past treatment protocols. Specifically, do these applied technologies increase live birth rates on a per cycle/first transfer basis? MATERIALS AND METHODS: An observational, retrospective cohort study of first transfer outcomes was performed in two groups. Group 1 (PGS) included PGS/VTF-all cycles, and group 2 (no PGS) included the first transfer from non-PGS fresh cycles or VTF-ALL cycles. In group 1, all blastocysts were biopsied on days 5/6, vitrified and array CGH performed. Group 2 patients had embryo transfers on day 3 or day 5. All blastocysts were vitrified and warmed according to μS-VTF protocols. Clinical pregnancies and implantation were confirmed by ultrasound and live birth information attained. Results were stratified by age with donor cycles excluded, and to eliminate bias, the same groups were then validated on a per cycle basis. Chi-squared used to determine significance. RESULTS: Analyzing 287 embryo transfers and 1,000+ PGS-tested blastocysts, an overall 97 % increase in live births favored group 1 (PGS). When utilizing PGS/VTF-ALL cycles, patients under 43 years old exhibited higher implantation, clinical pregnancy, and ongoing/live birth rates. Re-analyzing the data to include all cycles initiated revealed higher live birth rates in group 1 age groups ≤34 and 38–40 years old. CONCLUSION: Validating PGS on a per cycle basis eliminated data bias by including patients without blastocysts to biopsy or euploid embryos. Clearly, PGS uses blastocysts more efficiently to achieve success, while many women over 40 may benefit most by understanding why some failures occur. SUPPORT: None ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10815-016-0792-3) contains supplementary material, which is available to authorized users. Springer US 2016-08-20 2016-11 /pmc/articles/PMC5125149/ /pubmed/27544278 http://dx.doi.org/10.1007/s10815-016-0792-3 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Assisted Reproduction Technologies
Whitney, John B.
Schiewe, Mitchel C.
Anderson, Robert E.
Single center validation of routine blastocyst biopsy implementation
title Single center validation of routine blastocyst biopsy implementation
title_full Single center validation of routine blastocyst biopsy implementation
title_fullStr Single center validation of routine blastocyst biopsy implementation
title_full_unstemmed Single center validation of routine blastocyst biopsy implementation
title_short Single center validation of routine blastocyst biopsy implementation
title_sort single center validation of routine blastocyst biopsy implementation
topic Assisted Reproduction Technologies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125149/
https://www.ncbi.nlm.nih.gov/pubmed/27544278
http://dx.doi.org/10.1007/s10815-016-0792-3
work_keys_str_mv AT whitneyjohnb singlecentervalidationofroutineblastocystbiopsyimplementation
AT schiewemitchelc singlecentervalidationofroutineblastocystbiopsyimplementation
AT andersonroberte singlecentervalidationofroutineblastocystbiopsyimplementation